CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 249 enrolled
Drug / intervention
Ambroxol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00525044
NCT00525044Phase 3Completed
CompareCT.gov

Double-blind, Randomized, Placebo-controlled Trial to Investigate the Efficacy and Tolerance of Ambroxol Lozenges 20 mg in the Treatment of Sore Throat in Patients With Acute Viral Pharyngitis

Boehringer Ingelheim·interventional·Posted Sep 5, 2007·Updated Jul 11, 2019

In Brief

A Phase 3 clinical trial evaluating Ambroxol and Placebo for Pharyngitis. Completed, enrolled 249 participants across 4 sites.

Detailed Summary

The aim of this trial is to investigate the efficacy and tolerance of Ambroxol lozenges 20 mg in the treatment of sore throat in patients with acute viral pharyngitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharyngitis
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 5, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.8 years ago

Interventions

Ambroxoldrug

Placebodrug